Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223

BACKGROUND: Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration-resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijab, Adham, Curcean, Sebastian, Tunariu, Nina, Tovey, Holly, Alonzi, Roberto, Staffurth, John, Blackledge, Matthew, Padhani, Anwar, Tree, Alison, Stidwill, Helen, Finch, Jessica, Chatfield, Peter, Perry, Sophie, Mu Koh, Dow, Hall, Emma, Parker, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514085/
https://www.ncbi.nlm.nih.gov/pubmed/33958296
http://dx.doi.org/10.1016/j.clgc.2021.03.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514085/
https://www.ncbi.nlm.nih.gov/pubmed/33958296
http://dx.doi.org/10.1016/j.clgc.2021.03.020

Ejemplares similares